Device Trial Radar · NCT02032238
Clinical Efficacy of Bevacizumab Combined With Navigated Laser in Patients With Clinically Significant Macula Edema
Last checked: Nov 20, 2026Latest source record: Aug 11, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
12
Actual
Start
Mar 2013
Primary completion
Jun 2015
Study completion Jun 2015
Sponsor
- Lead sponsor
- OD-OS GmbHNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jan 9, 2014
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Asses efficacy of navigated laser in reducing the number of anti-VEGF injections as a prospective study using Bevacizumab.
Conditions
- Clinically Significant Macular Edema
Interventions
laser photocoagulationDevice
Standard bevacizumab Injections will be combined with laser photocoagulation in a pre-defined manner
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Eyes That Received RetreatmentTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Eye and Ear Infirmary
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.